Tissium, a French medtech company, has developed cutting-edge new materials called “biomorphic programmable polymers” that act as an adhesive, binding nerves together inside tissue without the need for invasive stitches or sutures. The aim is to reduce trauma to surrounding tissue and improve recovery rates. The material is already being used to repair heart defects, hernias, and damaged nerves.
In 2025, two Tissium products – one for nerve repair and another for hernia treatment – received approval from the US Food & Drug Administration (FDA). Shortly afterwards, a hospital in New Jersey announced the first commercial use of Tissium’s sutureless nerve-repair solution.
The company’s second product, for ventral hernia repair, is currently being submitted in Europe, where clinical studies and regulatory approvals are ongoing. Next in the pipeline is a cardiovascular sealing solution, alongside six additional applications for other parts of the body currently under development.
“The mission, the vision of the company, is to leverage this polymer platform to develop new atraumatic solutions to repair tissue,” says Tissium Chief Innovation Officer Maria Pereira, who co-founded the company in 2013 with Christophe Bancel, brother of Moderna CEO Stéphane Bancel. “It’s a material that can be activated on-demand, it can bind to tissues and be used in a controlled way by surgeons to enable atraumatic tissue repair in different therapeutic domains.”
To read the full article and gain access to over 1000 stories about the global tech sector become a paying subscriber to The Innovator. Click here to sign up.
